ArticleEJNMMI reports2026
Diagnostic accuracy of SPECT/CT in parathyroid adenoma detection: impact of radiopharmaceutical choice and quality control practices.
Article in EJNMMI reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the diagnostic accuracy of SPECT/CT for localizing parathyroid adenomas and to determine how radiopharmaceutical choice (MIBI vs. Myoview) and quality control (QC) practices affect detection performance and administered dose consistency in clinical practice.
methodsThis retrospective study included 136 patients who underwent dual-phase parathyroid scintigraphy with SPECT/CT at Al-Hada Armed Forces Hospital. Patients were classified into four groups according to radiopharmaceutical (MIBI or Myoview) and QC status (Regular or Irregular QC). Administered activity, detection accuracy, lesion localization, and concordance with surgical findings were assessed. Diagnostic performance was compared between SPECT/CT and planar imaging. Statistical analyses included ANOVA, χ² tests, and correlation analysis.
resultsSPECT/CT demonstrated significantly higher diagnostic accuracy than planar imaging across all groups. Regular QC conditions produced the most consistent administered activities and the highest detection rate (97.1%), whereas Irregular QC significantly reduced accuracy to 72.1%. MIBI showed superior performance under QC variability, maintaining higher sensitivity and more consistent lesion localization than Myoview. SPECT/CT also improved detection of ectopic and multi-gland disease compared with planar imaging.
conclusionSPECT/CT provides high diagnostic accuracy for parathyroid adenoma detection, but performance is strongly influenced by QC practices and, to a lesser extent, by radiopharmaceutical choice. Regular QC ensures optimal dose consistency and diagnostic reliability, while MIBI offers greater robustness under variable QC conditions. These findings support QC standardization and radiopharmaceutical selection as key determinants of improved clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.